Enovis Corporation (NYSE: ENOV) finalized the acquisition of LimaCorporate S.p.A., a major player in orthopedic solutions. This strategic move amplifies Enovis’ presence in orthopedic reconstruction, adding innovative implant solutions and 3D-printed Trabecular Titanium implants. The merger propels Enovis’ recon segment to a $1 billion revenue mark, strengthening its global market standing. Matt Trerotola, Enovis CEO, highlights the acquisition as a catalyst for growth, technology infusion, and increased shareholder value.
Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology growth company, today announced that it closed the acquisition of LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.
Lima strengthens Enovis’ position in the global orthopedic reconstruction market with a complementary portfolio of proven surgical solutions and technologies, which will accelerate global growth and margin expansion. In addition, Lima’s portfolio includes 3D printed Trabecular Titanium implants and a comprehensive revision offering in shoulders, which will further strengthen the Company’s position in the fast-growing extremities market.
“We are excited to welcome Lima’s talented team to Enovis. The combination brings Enovis’ recon segment to $1 billion in revenues and creates a fast-growing innovator in the global orthopedic reconstruction market. This is another great example of how we use strategic acquisitions to accelerate our growth, add great technologies and talent to our company, and drive compounding value for our shareholders,” said Matt Trerotola, Chair, and Chief Executive Officer of Enovis.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Bio Space